The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Visage Imaging, a subsidiary of Pro Medicus (PME), signs a $32 million, eight-year contract with Inova Health System
  • The contract will see Pro Medicus’ Image Visage 7 Enterprise Imaging Platform implemented throughout Inova and Fairfax Radiology
  • Visage 7 delivers quick, multi-dimensional images that are streamed through an intelligent thin-client viewer
  • Planning for the rollout of Visage 7 is expected to begin immediately with initial go-lives scheduled for the second half of the year
  • Pro Medicus was up 2.12 per cent with shares trading at $48.20

Visage Imaging, a subsidiary of Pro Medicus (PME), has signed a $32 million, eight-year contract with Inova Health System.

The contract will see Pro Medicus’ Image Visage 7 Enterprise Imaging Platform implemented throughout Inova and Fairfax Radiology.

Visage 7 delivers quick, multi-dimensional images that are streamed through an intelligent thin-client viewer (essentially a web-based document viewing and collaboration tool).

Planning for the rollout of Visage 7 is expected to begin immediately with initial go-lives scheduled for the second half of the year.

“This is our fourth major contract in the IDN space in less than 18 months which further underpins the strong momentum we continue to build not only in this segment of the market but also the North American market as a whole,” CEO Dr Sam Hupert said.

“Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloudnative technology provides us with a significant strategic advantage that addresses these opportunities across a growing segment of the market both in North America and other regions.”

Pro Medicus was up 2.12 per cent with shares trading at $48.20 at 3:24 pm AEST.

PME by the numbers
More From The Market Online
Silhouette of a person with a colourful brain

Emyria opens second Empax centre in Perth to meet mental health demand

Emyria Ltd has launched a second Empax clinic in Western Australia, aiming to support patients with…
Chromosomes concept

FDA OK for Neuren’s first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with…
3D illustration of the human brain

Argenica doses final patients in acute ischaemic stroke trial

Argenica Therapeutics Ltd has taken an important step in completion of its Phase 2 trial to…
A person counting money

Recce to raise $15.8M in trial funds through placement, entitlement offer

Recce Pharmaceuticals Ltd plans to raise $5 million through a Placement to a private investor in…